Novavax raises doubts about its ability to remain in business
By Michael Erman NEW YORK (Reuters) – COVID-19 vaccine maker Novavax Inc on Tuesday raised doubts about its ability to remain in business and announced plans to slash spendingĀ as it works to prepare for a fall vaccination campaign. The company said there is significant uncertainty around its 2023 revenue, funding from the U.S. government, and …
Novavax raises doubts about its ability to remain in business Read More »










